Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update
Novartis forecasts a decline in core operating profit for 2026 due to increased competition from generic drugs in the U.S., expecting a low single-digit drop. The company faces significant patent expirations, particularly for blockbuster drugs like Entresto and Promacta, which have already seen substantial sales declines. Despite this, Novartis anticipates a 5-6% annual sales growth through 2030. Fourth-quarter sales fell slightly to $13.34 billion, but core operating profit rose to $21.89 billion, slightly above analyst expectations.
marketscreener·
